Nevanac 1mg/ml drops 5 ml

Tradename:

Nevanac

Nevanak

Compound:

Each 1 ml suspension contains:

Nepafenac 1 mg

Auxiliary components:

benzalkonium chloride (in the form of a 50% solution), carbomer (974R), tyloxapol, disodium edetate, mannitol, sodium chloride, sodium hydroxide and / or hydrochloric acid – to adjust the pH, purified water.

Properties:

Nepafenac is a non-steroidal anti-inflammatory drug with analgesic action. When applied topically, nepafenac penetrates the cornea of ​​​​the eye and, under the influence of the hydrolase enzyme, is converted into the active form – amfenac. Amfenac inhibits the action of cyclooxygenase (prostaglandin – H synthase), an enzyme necessary for the production of prostaglandins.

Clinical Efficiency

In clinical studies on the effectiveness of Nepafenac suspension in the prevention and treatment of postoperative pain and inflammation in patients after cataract surgery, and to reduce the risk of postoperative macular edema in patients with diabetes who underwent cataract surgery, its high efficacy was established.

Indications:

– prevention and treatment of postoperative pain and inflammation after cataract surgery

– reduced risk of postoperative macular edema associated with cataract surgery in diabetic patients.

Dosage and administration:

Only for local use in ophthalmology.

Shake the bottle before use.

When using more than one topical ophthalmic drug, the interval between the use of drugs should be at least 5 minutes.

Do not touch the dropper tip of the vial to the eyes or any other surface to avoid contamination of the dropper tip and the contents of the vial.

After use, it is recommended to close the bottle tightly with a cap.

For the prevention and treatment of postoperative pain and inflammation, 1 drop of the drug is instilled into the conjunctival sac of the affected eye(s) 3 times a day, starting 1 day before cataract surgery and up to 14 days of the postoperative period. 30 – 120 minutes before operation, one more drop should be instilled.

Treatment may be extended up to 3 weeks (21 days) postoperatively, as directed by the physician.

Children.

The safety and efficacy of Nevanak eye drops in patients under 18 years of age have not been studied and, therefore, the use of the drug for such patients is not recommended.

Contraindications:

Individual hypersensitivity to the active substance, any excipient or other non-steroidal anti-inflammatory drugs (NSAIDs).

Precautionary measures:

The use of NSAIDs locally can lead to the development of keratitis. In some susceptible patients, prolonged topical use of NSAIDs can lead to epithelial damage, corneal thinning, corneal erosion, corneal ulceration or perforation. Such phenomena can threaten vision. Patients who develop signs of corneal damage should immediately stop using Nevanak, and the condition of the cornea should be carefully monitored.

Topical application of NSAIDs may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Simultaneous topical use of NSAIDs and steroid drugs can slow down the healing process.

Side effects:

Uncommon: keratitis, punctate keratitis, corneal epithelial defect, allergic conjunctivitis, eye pain, foreign body sensation, eyelid margin peeling

Rare: Blurred vision, photophobia, dry eyes, blepharitis, eye irritation, itchy eyes, discharge from the eyes, increased tearing.

Ophthalmic disorders:

corneal perforation, ulcerative keratitis, corneal thinning, corneal opacity, corneal scar, healing (corneal) failure, decreased visual acuity, eye swelling, eye hyperemia

Gastrointestinal Disorders:

vomit

Research:

increase in blood pressure.

Storage method:

At a temperature not higher than 25 degrees. After opening, store no longer than 28 days.

Package:

The cardboard box contains 5 ml in a bottle with a dispenser.